RS20050226A - EIKOSAPENTAENOIČNA KISELINA (EPA) ZA LEČENjE ANOREXIA NERVOSA I BULIMIJE - Google Patents

EIKOSAPENTAENOIČNA KISELINA (EPA) ZA LEČENjE ANOREXIA NERVOSA I BULIMIJE

Info

Publication number
RS20050226A
RS20050226A YUP-2005/0226A YUP20050226A RS20050226A RS 20050226 A RS20050226 A RS 20050226A YU P20050226 A YUP20050226 A YU P20050226A RS 20050226 A RS20050226 A RS 20050226A
Authority
RS
Serbia
Prior art keywords
epa
use according
acid
treatment
day
Prior art date
Application number
YUP-2005/0226A
Other languages
English (en)
Serbian (sr)
Inventor
David Frederick Horrobin
Agnes Ayton
Original Assignee
Laxdale Limited,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20050226(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laxdale Limited, filed Critical Laxdale Limited,
Publication of RS20050226A publication Critical patent/RS20050226A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
YUP-2005/0226A 2002-09-16 2003-09-16 EIKOSAPENTAENOIČNA KISELINA (EPA) ZA LEČENjE ANOREXIA NERVOSA I BULIMIJE RS20050226A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221480.7A GB0221480D0 (en) 2002-09-16 2002-09-16 Treatment of anorexia nervosa (AN) and bulimia
PCT/GB2003/003985 WO2004024136A1 (en) 2002-09-16 2003-09-16 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia

Publications (1)

Publication Number Publication Date
RS20050226A true RS20050226A (sr) 2007-09-21

Family

ID=9944164

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0226A RS20050226A (sr) 2002-09-16 2003-09-16 EIKOSAPENTAENOIČNA KISELINA (EPA) ZA LEČENjE ANOREXIA NERVOSA I BULIMIJE

Country Status (20)

Country Link
US (1) US20060135608A1 (enExample)
EP (1) EP1556028A1 (enExample)
JP (1) JP2006503031A (enExample)
KR (1) KR20050042823A (enExample)
CN (1) CN1694694A (enExample)
AU (1) AU2003269138A1 (enExample)
BR (1) BR0317857A (enExample)
CA (1) CA2499142A1 (enExample)
GB (1) GB0221480D0 (enExample)
HR (1) HRP20050245A2 (enExample)
IS (1) IS7744A (enExample)
MX (1) MXPA05002943A (enExample)
NO (1) NO20051847L (enExample)
NZ (1) NZ538793A (enExample)
PL (1) PL375726A1 (enExample)
RS (1) RS20050226A (enExample)
RU (1) RU2330653C2 (enExample)
TW (1) TW200410682A (enExample)
WO (1) WO2004024136A1 (enExample)
ZA (1) ZA200502161B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
WO2005046668A1 (ja) * 2003-11-14 2005-05-26 Mochida Pharmaceutical Co., Ltd. 言語障害予防・治療剤
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
CA2672513C (en) 2007-02-15 2010-05-25 Centre De Recherche Sur Les Biotechnologies Marines Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US8816110B2 (en) 2007-02-15 2014-08-26 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
BRPI1011883A2 (pt) * 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
AU2012214260A1 (en) * 2011-02-11 2013-07-25 E. I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
US9447020B2 (en) 2013-10-31 2016-09-20 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
RU2545988C1 (ru) * 2013-11-12 2015-04-10 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы Способ лечения хронического запора и функциональной анорексии
WO2019153073A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
US20210130897A1 (en) * 2018-04-16 2021-05-06 Quadrant Biosciences Inc. Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status
US11166933B2 (en) 2018-05-03 2021-11-09 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN109276262B (zh) * 2018-07-30 2021-01-26 中国科学院心理研究所 一种用于筛选高危进食障碍的检测系统
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
US12144786B2 (en) 2020-03-27 2024-11-19 Homeostasis Therapeutics LLC Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes

Also Published As

Publication number Publication date
NZ538793A (en) 2007-05-31
NO20051847L (no) 2005-04-15
ZA200502161B (en) 2005-09-15
US20060135608A1 (en) 2006-06-22
CN1694694A (zh) 2005-11-09
PL375726A1 (en) 2005-12-12
WO2004024136A1 (en) 2004-03-25
KR20050042823A (ko) 2005-05-10
EP1556028A1 (en) 2005-07-27
CA2499142A1 (en) 2004-03-25
BR0317857A (pt) 2005-12-06
JP2006503031A (ja) 2006-01-26
MXPA05002943A (es) 2005-06-03
AU2003269138A1 (en) 2004-04-30
GB0221480D0 (en) 2002-10-23
HRP20050245A2 (en) 2005-10-31
IS7744A (is) 2005-03-15
RU2330653C2 (ru) 2008-08-10
TW200410682A (en) 2004-07-01
RU2005107416A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
Drabińska et al. Recent advances in the application of a ketogenic diet for obesity management
RU2330653C2 (ru) Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии
JP7278593B2 (ja) 外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート
Andersen et al. Anorexia nervosa in the male: An underdiagnosed disorder
Anekwe et al. Ketogenic diet-induced elevated cholesterol, elevated liver enzymes and potential non-alcoholic fatty liver disease
JP7761372B2 (ja) 対象におけるマイトファジーを改善するための方法
JP2023100869A (ja) 対象におけるマイトファジーを改善するための方法
US20090012039A1 (en) Use of methylcobalamin nasal spray to treat disorders
US20260053764A1 (en) Composition for preventing deterioration in cognitive function and/or improving cognitive function
WO2022210856A1 (ja) 睡眠の質を改善するための組成物
JP6368368B2 (ja) ｐ−アニスアルデヒドを使用する組成物及び方法
Cott Controlled fasting treatment for schizophrenia
US20220047611A1 (en) Capsule, Tablet or Pill
Miller et al. The Life Extension Revolution: The New Science of Growing Older Without Aging
WO2022244727A1 (ja) 認知機能を改善するための組成物
Sato et al. Effects of Oral Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Body Weight in Two Adult Patients with Down Syndrome and Type 2 Diabetes: A Case Report
WO2025135023A1 (ja) 目の不調を改善するための組成物
Noland Lipidomics: Clinical Application
Prousky et al. A case report on the successful use of inositol hexaniacinate for the treatment of achlorhydria: its possible mechanism of action upon the central nervous system and parietal cell-adenosine Triphosphate-dependent [K. sup.+]/[H. sup.+] pump
CN115697488A (zh) 用于改善认知功能的mct配制物
PeaceHealth et al. Fish Oil & Cod Liver Oil (EPA & DHA)
Wilbur The Physician and The National Nutrition Program
Danford et al. Report on the Fourth Conference for Federally Supported Human Nutrition Research Units and Centers
Tolbert Enhancing weight gain in long-term care residents at risk for weight loss through protein and calorie fortification
Conte Effective natural weight loss techniques